Skip to main content
Top
Published in: Journal of Medical Case Reports 1/2012

Open Access 01-12-2012 | Case report

Development of low blood glucose readings in nine non-diabetic patients treated with tumor necrosis factor-alpha inhibitors: a case series

Authors: Jadwiga B Czajkowska, Brandon Shutty, Susan Zito

Published in: Journal of Medical Case Reports | Issue 1/2012

Login to get access

Abstract

Introduction

Treatment with various biological agents in disease states such as rheumatoid arthritis has been associated with multiple side effects. Whereas many of these are frequently reported in the literature, hypoglycemia, a possible side effect of tumor necrosis factor-alpha inhibitors, may be underpublicized.

Case presentation

We report nine cases of non-diabetic Caucasian women who were between 29 and 68 years of age and who developed low glucose readings after treatment with tumor necrosis factor-alpha inhibitors. We provide a more detailed discussion of existing evidence of the role of tumor necrosis factor-alpha in the pathogenesis of inflammation and its impact on glycemic equilibrium.

Conclusions

Physicians using tumor necrosis factor-alpha inhibitors in the treatment of various rheumatic and other autoimmune diseases should be aware of the potential for the development of glycemic disturbance in these patients. A further role of tumor necrosis factor-alpha inhibitors in the glycemic equilibrium warrants larger controlled trials in patients with and those without a history of diabetes.
Literature
1.
go back to reference Lloyd S, Bujkiewicz S, Wailoo AJ, Sutton AJ, Scott D: The effectiveness of anti-TNF- {alpha} therapies when used sequentially in rheumatoid arthritis patients: a systematic review and meta-analysis. Rheumatology (Oxford). 2010, 49: 2313-2321. 10.1093/rheumatology/keq169.CrossRef Lloyd S, Bujkiewicz S, Wailoo AJ, Sutton AJ, Scott D: The effectiveness of anti-TNF- {alpha} therapies when used sequentially in rheumatoid arthritis patients: a systematic review and meta-analysis. Rheumatology (Oxford). 2010, 49: 2313-2321. 10.1093/rheumatology/keq169.CrossRef
2.
go back to reference Ferkolj I: How to improve the safety of biologic therapy in Crohn's disease. J Physiol Pharmacol. 2009, 60 (Suppl 7): 67-70.PubMed Ferkolj I: How to improve the safety of biologic therapy in Crohn's disease. J Physiol Pharmacol. 2009, 60 (Suppl 7): 67-70.PubMed
3.
go back to reference Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, Martín Mola E, Pavelka K, Sany J, Settas L, Wajdula J, Pedersen R, Fatenejad S, Sanda M, TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators: Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomized controlled trial. Lancet. 2004, 363: 675-681. 10.1016/S0140-6736(04)15640-7.CrossRefPubMed Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, Martín Mola E, Pavelka K, Sany J, Settas L, Wajdula J, Pedersen R, Fatenejad S, Sanda M, TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators: Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomized controlled trial. Lancet. 2004, 363: 675-681. 10.1016/S0140-6736(04)15640-7.CrossRefPubMed
4.
go back to reference Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, Fischkoff SA, Chartash EK: Radiographic, clinical and functional outcomes of treatment with adalimumab (a human anti tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy. A randomized, placebo controlled, 52-week trial. Arthritis Rheum. 2004, 50: 1400-1411. 10.1002/art.20217.CrossRefPubMed Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, Fischkoff SA, Chartash EK: Radiographic, clinical and functional outcomes of treatment with adalimumab (a human anti tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy. A randomized, placebo controlled, 52-week trial. Arthritis Rheum. 2004, 50: 1400-1411. 10.1002/art.20217.CrossRefPubMed
5.
go back to reference St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, Keystone E, Schiff M, Kalden JR, Wang B, Dewoody K, Weiss R, Baker D, Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group: Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled study. Arthritis Rheum. 2004, 50: 3432-3443. 10.1002/art.20568.CrossRefPubMed St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, Keystone E, Schiff M, Kalden JR, Wang B, Dewoody K, Weiss R, Baker D, Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group: Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled study. Arthritis Rheum. 2004, 50: 3432-3443. 10.1002/art.20568.CrossRefPubMed
6.
go back to reference Goren I, Muller E, Pfeilschifter J, Frank S: Severely impaired insulin signaling in chronic wounds of diabetic ob/ob mice: a potential role of tumor necrosis factor-alpha. Am J Pathol. 2006, 168: 765-777. 10.2353/ajpath.2006.050293.CrossRefPubMedPubMedCentral Goren I, Muller E, Pfeilschifter J, Frank S: Severely impaired insulin signaling in chronic wounds of diabetic ob/ob mice: a potential role of tumor necrosis factor-alpha. Am J Pathol. 2006, 168: 765-777. 10.2353/ajpath.2006.050293.CrossRefPubMedPubMedCentral
7.
go back to reference Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G: Adipose tissue necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab. 2001, 280: E745-751.PubMed Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G: Adipose tissue necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab. 2001, 280: E745-751.PubMed
8.
go back to reference Yazdani-Biuki B, Stelzl H, Brezinschek HP, Hermann J, Mueller T, Krippl P, Graninger W, Wascher TC: Improvement of insulin sensitivity in insulin resistant subjects during prolonged treatment with the anti-TNF alpha antibody infliximab. Eur J Clin Invest. 2004, 34: 641-642. 10.1111/j.1365-2362.2004.01390.x.CrossRefPubMed Yazdani-Biuki B, Stelzl H, Brezinschek HP, Hermann J, Mueller T, Krippl P, Graninger W, Wascher TC: Improvement of insulin sensitivity in insulin resistant subjects during prolonged treatment with the anti-TNF alpha antibody infliximab. Eur J Clin Invest. 2004, 34: 641-642. 10.1111/j.1365-2362.2004.01390.x.CrossRefPubMed
9.
go back to reference Young V, Kormos W, Chick D, Goroll A: Blueprints Medicine. 2007, Philadelphia: Lippincott Williams & Wilkins, 294-4 Young V, Kormos W, Chick D, Goroll A: Blueprints Medicine. 2007, Philadelphia: Lippincott Williams & Wilkins, 294-4
10.
go back to reference Boulton J, Bourne J: Unstable diabetes in a patient receiving anti-TNF-alpha for rheumatoid arthritis. Rheumatology (Oxford). 2007, 46: 178-179. 10.1093/rheumatology/kel322.CrossRef Boulton J, Bourne J: Unstable diabetes in a patient receiving anti-TNF-alpha for rheumatoid arthritis. Rheumatology (Oxford). 2007, 46: 178-179. 10.1093/rheumatology/kel322.CrossRef
11.
go back to reference Bonilla E, Lee YY, Phillips PE, Perl A: Hypoglycemia after initiation of treatment with etanercept in a patient with type 2 diabetes mellitus. Ann Rheum Dis. 2001, 66: 1688-CrossRef Bonilla E, Lee YY, Phillips PE, Perl A: Hypoglycemia after initiation of treatment with etanercept in a patient with type 2 diabetes mellitus. Ann Rheum Dis. 2001, 66: 1688-CrossRef
12.
go back to reference Farrokhi F, Taylor HC, McBride NM: Etanercept-induced hypoglycemia and improved glycemnic control in a patient with type 2 diabetes. Endocr Pract. 2011, 17: 306-307.CrossRefPubMed Farrokhi F, Taylor HC, McBride NM: Etanercept-induced hypoglycemia and improved glycemnic control in a patient with type 2 diabetes. Endocr Pract. 2011, 17: 306-307.CrossRefPubMed
13.
go back to reference Wambier CG, Foss-Freitas MC, Paschoal RS, Tomazini MV, Simao JC, Foss MC, Foss NT: Severe hypoglycemia after initiation of anti-tumor necrosis factor therapy with etanercet in a patient with generalized pustular psoriasis and type 2 diabetes mellitus. J Am Acad Dermatol. 2009, 60: 883-885. 10.1016/j.jaad.2008.10.009.CrossRefPubMed Wambier CG, Foss-Freitas MC, Paschoal RS, Tomazini MV, Simao JC, Foss MC, Foss NT: Severe hypoglycemia after initiation of anti-tumor necrosis factor therapy with etanercet in a patient with generalized pustular psoriasis and type 2 diabetes mellitus. J Am Acad Dermatol. 2009, 60: 883-885. 10.1016/j.jaad.2008.10.009.CrossRefPubMed
14.
go back to reference Cheung D, Bryer-Ash M: Persistent hypoglycemia in a patient with diabetes taking etanercept for the treatment of psoriasis. J Am Acad Dermatol. 2009, 60: 1032-1036. 10.1016/j.jaad.2008.12.012.CrossRefPubMed Cheung D, Bryer-Ash M: Persistent hypoglycemia in a patient with diabetes taking etanercept for the treatment of psoriasis. J Am Acad Dermatol. 2009, 60: 1032-1036. 10.1016/j.jaad.2008.12.012.CrossRefPubMed
15.
go back to reference Mastrandrea L, Yu J, Behrens T, Buchlis J, Albini C, Fourtner S, Quattrin T: Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study. Diabetes Care. 2009, 32: 1244-1249. 10.2337/dc09-0054.CrossRefPubMedPubMedCentral Mastrandrea L, Yu J, Behrens T, Buchlis J, Albini C, Fourtner S, Quattrin T: Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study. Diabetes Care. 2009, 32: 1244-1249. 10.2337/dc09-0054.CrossRefPubMedPubMedCentral
16.
go back to reference Smith D, Amiel S: Hypoglycaemia unawareness and the brain. Diabetologia. 2001, 45: 945-958. Smith D, Amiel S: Hypoglycaemia unawareness and the brain. Diabetologia. 2001, 45: 945-958.
17.
go back to reference Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998, 15: 539-553. 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S.CrossRefPubMed Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998, 15: 539-553. 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S.CrossRefPubMed
18.
go back to reference Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM: IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science. 1996, 271: 665-668. 10.1126/science.271.5249.665.CrossRefPubMed Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM: IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science. 1996, 271: 665-668. 10.1126/science.271.5249.665.CrossRefPubMed
19.
go back to reference Senn JJ, Klover PJ, Nowak IA, Zimmers TA, Koniaris LG, Furlanetto RW, Mooney RA: Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem. 2003, 278: 13740-13746. 10.1074/jbc.M210689200.CrossRefPubMed Senn JJ, Klover PJ, Nowak IA, Zimmers TA, Koniaris LG, Furlanetto RW, Mooney RA: Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem. 2003, 278: 13740-13746. 10.1074/jbc.M210689200.CrossRefPubMed
20.
go back to reference Emanuelli B, Peraldi P, Filloux C, Chavey C, Freidinger K, Hilton DJ, Hotamisligil GS, Van Obberghen E: SOCS-3 inhibits insulin signaling and is up-regulated in response to tumor necrosis factor-alpha in the adipose tissue of obese mice. J Biol Chem. 2001, 276: 47944-47949.CrossRefPubMed Emanuelli B, Peraldi P, Filloux C, Chavey C, Freidinger K, Hilton DJ, Hotamisligil GS, Van Obberghen E: SOCS-3 inhibits insulin signaling and is up-regulated in response to tumor necrosis factor-alpha in the adipose tissue of obese mice. J Biol Chem. 2001, 276: 47944-47949.CrossRefPubMed
21.
go back to reference Rui L, Yuan M, Frantz D, Shoelson S, White MF: SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J Biol Chem. 2002, 277: 42394-42398. 10.1074/jbc.C200444200.CrossRefPubMed Rui L, Yuan M, Frantz D, Shoelson S, White MF: SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J Biol Chem. 2002, 277: 42394-42398. 10.1074/jbc.C200444200.CrossRefPubMed
22.
go back to reference Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM: Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature. 1999, 399: 601-605. 10.1038/21224.CrossRefPubMed Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM: Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature. 1999, 399: 601-605. 10.1038/21224.CrossRefPubMed
23.
go back to reference Du K, Herzig S, Kulkarni RN, Montminy M: TRB3: a tribbles homolog that inhibits Akt/PKB activation by insulin in liver. Science. 2003, 300: 1574-1577. 10.1126/science.1079817.CrossRefPubMed Du K, Herzig S, Kulkarni RN, Montminy M: TRB3: a tribbles homolog that inhibits Akt/PKB activation by insulin in liver. Science. 2003, 300: 1574-1577. 10.1126/science.1079817.CrossRefPubMed
Metadata
Title
Development of low blood glucose readings in nine non-diabetic patients treated with tumor necrosis factor-alpha inhibitors: a case series
Authors
Jadwiga B Czajkowska
Brandon Shutty
Susan Zito
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Journal of Medical Case Reports / Issue 1/2012
Electronic ISSN: 1752-1947
DOI
https://doi.org/10.1186/1752-1947-6-5

Other articles of this Issue 1/2012

Journal of Medical Case Reports 1/2012 Go to the issue